Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

Healthcare Medical Devices
MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid... see more

Recent & Breaking News (TSXV:MIR)

MedMira Announces the appointment of Vice President of Commercial Operations

Accesswire October 3, 2024

Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada

Accesswire August 13, 2024

MedMira Reports Third Quarter Results FY2024

Accesswire July 2, 2024

MedMira Announces the Hire of Vice President of Business Development

Accesswire April 30, 2024

MedMira Reports Second Quarter Results FY2024

Accesswire April 1, 2024

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Accesswire March 13, 2024

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products

Accesswire February 1, 2024

Corporate Update on Clinical Evaluation of MedMira's Products

Accesswire February 1, 2024

MedMira Reports First Quarter Results FY2024

Accesswire December 29, 2023

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

Accesswire December 13, 2023

MedMira Reports FY2023 Fourth Quarter and Year End Financial Results

Accesswire November 28, 2023

Update on MedMira's Regulatory Path in Canada and the USA

Accesswire September 27, 2023

Canadian Investment Regulatory Organization Trade Resumption - MIR

Canada NewsWire August 31, 2023

Progress Update on Securities

Accesswire August 30, 2023

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire August 30, 2023

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire August 29, 2023

Canadian Investment Regulatory Organization Trading Halt - MIR

Canada NewsWire August 29, 2023

MedMira Reports Third Quarter Results FY2023

Accesswire June 29, 2023

MedMira Reports Second Quarter Results FY2023

Accesswire April 3, 2023

Update on MedMira's Reveal TP (Syphilis) Clinical Trials in Canada

Accesswire March 14, 2023